For people with mild cognitive impairment (MCI), a stage with noticeable memory changes but preserved daily function, the LiBBY findings change nothing yet. LiBBY, the THC-CBD agitation trial, enrolled only people with late-stage dementia receiving end-of-life care, not people with MCI. The Phase 2 trial reported results for the first time on July 14, 2026, at AAIC 2026 in London. The Alzheimer's Association said participants took a rapid-acting oil with 2 mg THC plus 100 mg CBD twice daily in Alzheimer's Association trial summary.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did LiBBY test?
- How large were benefits and harms?
- Why do findings not transfer to MCI?
- What should you do now?
What did LiBBY test?
NeurologyLive reported LiBBY enrolled 120 participants with major neurocognitive disorder and significant agitation. Their mean age was 80. All were hospice-eligible or receiving end-of-life dementia care at 10 U.S.
sites. The treatment was T2:C100, an oral oil with purified THC, the intoxicating cannabis compound, and CBD, the non-intoxicating compound. People took it twice daily for 12 weeks. Staff visited them at home or in their residence.
How large were benefits and harms?
Agitation scores on the Cohen-Mansfield Agitation Inventory, a caregiver rating of restless and aggressive behaviors, fell more with THC/CBD than placebo at week 2. The drop was 10.61 points versus 4.35 points. Separation lasted through week 12. Clinician-rated improvement reached 83.9% versus 30.5% at week 2 and 87.2% versus 23.6% at week 12, according to NeurologyLive report on the AAIC presentation.
Overall adverse events were similar between groups. Serious events were higher with THC/CBD, at 23.3% versus 11.9%. Serious infections drove much of the gap, at 11.7% versus 1.7%. Deaths were also higher, at 13.1% versus 5.1%, NeurologyLive reported.
Why do findings not transfer to MCI?
MCI preserves routine daily function and is distinct from dementia. The Northwestern Mesulam Institute MCI guide draws that line clearly. LiBBY studied only advanced hospice-eligible dementia with agitation.
LiBBY also tested only one supervised product and dose. Results do not transfer to dispensary or over-the-counter cannabis, the LiBBY Study results page states. A late-life agitation crisis differs from early forgetfulness.
What should you do now?
Do not seek THC/CBD for MCI because of LiBBY. The balance of benefit and serious harm in end-of-life dementia does not predict benefit in MCI.
Any cannabis use needs direct medical supervision. Bring your question list to your next memory-care visit instead of changing anything now. Ask what new evidence would actually change your plan.
- Ask your memory-care team what explains your symptoms and what follow-up is planned.
- Bring all prescriptions, sleep aids, alcohol use, and behavior concerns to that visit.
- If you support someone with late-stage agitation, ask the hospice or palliative team about safe options.
You Might Also Like
- Dementia With Multiple Etiologies in the 2026 NIA Report: Study Design and Evidence Limits for People With Mild Cognitive Impairment
- Injection Training for the 2026 At-Home Leqembi Regimen: A Preparation Checklist for People With Early Alzheimer’s
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: A Preparation Checklist for People With Early Alzheimer’s
